Development PipelineSGN-CEACAM5C

an investigational topoisomerase I inhibitor antibody-drug conjugate targeting CEACAM5

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Clinical Trials

SGNCEA5C-001: Advanced solid tumors

  • Phase 1

  • Phase 2

  • Phase 3

Program Resources

Detailed information about SGN-CEACAM5C clinical trials